Loading
Life sciences · Journal article
Diabetes Obesity and Metabolism · August 9, 2026
Raises a question worth testing. It does not answer one.
This is a mechanistic study demonstrating that inhibition of mitochondrial Complex I by rotenone or NDUFS4 knockdown reduces palmitic acid–induced mitochondrial oxidative stress and improves endothelial function in cultured endothelial cells and high-fat diet–fed mice. The work identifies Complex I dysregulation as a potential contributor to lipotoxic vascular injury but provides no human data and is exploratory in nature.
Experimental mechanistic study: in vitro cell culture and in vivo mouse model. Human aortic endothelial cells; high-fat diet–fed mice. Intervention: Rotenone (Complex I inhibitor) or NDUFS4-targeting siRNA in vitro; rotenone administration in vivo. Compared with: Palmitic acid–treated cells without intervention; HFD-fed mice without rotenone treatment.
Palmitic acid lowered the NAD+/NADH ratio and increased NADH-linked Complex I activity, a redox state consistent with enhanced Complex I–linked ROS generation Rotenone (Complex I inhibitor) suppressed mtROS overproduction, improved NAD+/NADH balance, and improved endothelial function in vitro NDUFS4 knockdown achieved similar mitochondrial and endothelial dysfunction improvements as rotenone
Rotenone is a pesticide; clinical safety and tolerability as a therapeutic agent not addressed
These findings are preclinical and mechanistic. They suggest a potential therapeutic target but do not yet support clinical intervention; human studies would be needed to assess safety and efficacy of Complex I modulation in obesity and diabetes.
Mechanistic proof-of-concept study in cell culture and rodent models identifying a pathway but lacking human efficacy or safety data needed to guide clinical practice.
As stated by the source record.
These findings are preclinical and mechanistic. They suggest a potential therapeutic target but do not yet support clinical intervention; human studies would be needed to assess safety and efficacy of Complex I modulation in obesity and diabetes.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
ABSTRACT Background Endothelial dysfunction induced by elevated free fatty acids is a critical initiating event in diabetic macrovascular complications. While mitochondrial reactive oxygen species (mtROS) are key mediators of this lipotoxic injury, the specific contribution of mitochondrial Complex I dynamics and its associated redox regulation remains to be fully elucidated. Methods We investigated the therapeutic potential of targeting mitochondrial Complex I in lipotoxicity‐induced endothelial injury. Using rotenone (a Complex I inhibitor) and NDUFS4 [NADH Dehydrogenase (Ubiquinone) Fe‐S Protein 4]‐targeting siRNA, we performed in vitro interventions in palmitic acid‐treated human aortic endothelial cells and in vivo studies in high‐fat diet (HFD)‐fed mice. Results Palmitic acid triggered endothelial dysfunction accompanied by pronounced mitochondrial oxidative stress. Mechanistically, palmitic acid lowered the oxidised/reduced nicotinamide adenine dinucleotide (NAD + /NADH) ratio and increased NADH‐linked Complex I activity, a redox state consistent with enhanced Complex I‐linked ROS generation. Pharmacological (rotenone) or genetic ( NDUFS4 knockdown) modulation of Complex I activity suppressed mtROS overproduction, improved NAD + /NADH balance, alleviated oxidative stress and improved endothelial function. In vivo, rotenone attenuated HFD‐induced systemic metabolic disturbances and vascular oxidative stress while improving endothelial barrier integrity and angiogenic responses. Conclusions Our study suggests that dysregulated mitochondrial Complex I activity may serve as an important contributor to lipotoxic endothelial injury. These findings support Complex I modulation as a potential strategy to mitigate free fatty acid‐induced endothelial dysfunction in obesity‐ and diabetes‐related vascular complications.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.